Federica Tavaglione
Rome, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 58 publications
Longitudinal Validation of Clinical Care Pathways for Metabolic Dysfunction-Associated Steatotic Liver Disease in a Prospective Cohort of Individuals With Type 2 Diabetes.
Journal: Gastro hep advances
Published: March 18, 2026
Emerging role of GLP-1 mono, dual, and triple agonists in the management of MASH-related fibrosis.
Journal: Cell reports. Medicine
Published: March 18, 2026
Reply to: "Limited clinical utility of serum-based ELISA PEth compared with whole-blood LC-MS/MS PEth to quantify alcohol consumption".
Journal: Journal of hepatology
Published: November 17, 2025
Factors associated with protection from MASLD in type 2 diabetes: A prospective study integrating longitudinal MRI/MRE and stable isotope tracing.
Journal: JHEP reports : innovation in hepatology
Published: October 20, 2025
Reply to: "Beyond a single snapshot: Considerations for PEth-guided subclassification of steatotic liver disease".
Journal: Journal of hepatology
Published: September 23, 2025
Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease.
Journal: Nature reviews. Gastroenterology & hepatology
Published: August 28, 2025
The MetALD-ALD Prediction Index: A Phosphatidylethanol-Driven Biomarker Panel for Identifying Individuals With Steatotic Liver Disease and Excessive Alcohol Use.
Journal: Gastroenterology
Published: July 17, 2025
Ultrasound-derived visceral adipose tissue as a reliable marker of hepato-metabolic risk in patients with MASLD.
Journal: Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
Published: July 14, 2025
Review Article: GLP-1 Receptor Agonists and Glucagon/GIP/GLP-1 Receptor Dual or Triple Agonists-Mechanism of Action and Emerging Therapeutic Landscape in MASLD.
Journal: Alimentary pharmacology & therapeutics
Published: March 21, 2025
Decreased degree of adipocyte differentiation in visceral adipose tissue contributes to metabolic dysfunction-associated steatotic liver disease.
Journal: Nature communications
Published: March 03, 2025
Genome-wide interaction study with body mass index identifies CYP7A1 and GIPR as genetic modulators of metabolic dysfunction-associated steatotic liver disease.
Journal: Clinical and molecular hepatology
Published: February 26, 2025
Last Updated: 09/26/2026